Jinyu Bio-Technology Co Ltd (600201) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jinyu Bio-Technology Co Ltd (600201) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥102.68 Million ≈ $15.03 Million USD) by net assets (CN¥5.65 Billion ≈ $827.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Jinyu Bio-Technology Co Ltd to measure how many days the company can operate on defensive assets alone.
Jinyu Bio-Technology Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Jinyu Bio-Technology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jinyu Bio-Technology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jinyu Bio-Technology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Syngene International Limited
NSE:SYNGENE
|
-0.010x |
|
Zhengzhou GL Tech Co Ltd
SHE:300480
|
-0.004x |
|
Terravest Capital Inc
TO:TVK
|
0.038x |
|
IBI Inv House
TA:IBI
|
0.094x |
|
Nyocor Co Ltd
SHG:600821
|
0.138x |
|
Pitney Bowes Inc
NYSE:PBI
|
-0.291x |
|
OEM International AB (publ)
ST:OEM-B
|
0.095x |
|
Henan Hanwei Electronics Co
SHE:300007
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Jinyu Bio-Technology Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Jinyu Bio-Technology Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see 600201 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.55 Billion ≈ $812.27 Million |
CN¥316.12 Million ≈ $46.26 Million |
0.057x | +6.51% |
| 2024-12-31 | CN¥5.42 Billion ≈ $792.44 Million |
CN¥289.55 Million ≈ $42.37 Million |
0.053x | -27.11% |
| 2023-12-31 | CN¥5.65 Billion ≈ $827.50 Million |
CN¥414.83 Million ≈ $60.70 Million |
0.073x | +13.87% |
| 2022-12-31 | CN¥5.35 Billion ≈ $782.82 Million |
CN¥344.65 Million ≈ $50.43 Million |
0.064x | -32.80% |
| 2021-12-31 | CN¥5.56 Billion ≈ $813.64 Million |
CN¥533.08 Million ≈ $78.01 Million |
0.096x | -27.88% |
| 2020-12-31 | CN¥5.26 Billion ≈ $770.13 Million |
CN¥699.61 Million ≈ $102.38 Million |
0.133x | +59.72% |
| 2019-12-31 | CN¥4.87 Billion ≈ $712.50 Million |
CN¥405.24 Million ≈ $59.30 Million |
0.083x | +2.89% |
| 2018-12-31 | CN¥5.22 Billion ≈ $764.23 Million |
CN¥422.46 Million ≈ $61.82 Million |
0.081x | -59.37% |
| 2017-12-31 | CN¥4.48 Billion ≈ $655.26 Million |
CN¥891.44 Million ≈ $130.45 Million |
0.199x | -1.20% |
| 2016-12-31 | CN¥3.75 Billion ≈ $549.13 Million |
CN¥756.12 Million ≈ $110.64 Million |
0.201x | -15.68% |
| 2015-12-31 | CN¥2.07 Billion ≈ $302.70 Million |
CN¥494.32 Million ≈ $72.33 Million |
0.239x | -33.42% |
| 2014-12-31 | CN¥1.63 Billion ≈ $238.59 Million |
CN¥585.19 Million ≈ $85.63 Million |
0.359x | -29.15% |
| 2013-12-31 | CN¥1.28 Billion ≈ $187.57 Million |
CN¥649.34 Million ≈ $95.02 Million |
0.507x | +430.26% |
| 2012-12-31 | CN¥1.08 Billion ≈ $157.69 Million |
CN¥102.95 Million ≈ $15.06 Million |
0.096x | -48.88% |
| 2011-12-31 | CN¥991.13 Million ≈ $145.03 Million |
CN¥185.20 Million ≈ $27.10 Million |
0.187x | +264.74% |
| 2010-12-31 | CN¥844.15 Million ≈ $123.53 Million |
CN¥-95.75 Million ≈ $-14.01 Million |
-0.113x | -247.73% |
| 2009-12-31 | CN¥750.98 Million ≈ $109.89 Million |
CN¥-24.50 Million ≈ $-3.58 Million |
-0.033x | -110.54% |
| 2008-12-31 | CN¥723.47 Million ≈ $105.87 Million |
CN¥223.91 Million ≈ $32.77 Million |
0.309x | +61.13% |
| 2007-12-31 | CN¥708.54 Million ≈ $103.68 Million |
CN¥136.09 Million ≈ $19.91 Million |
0.192x | +13.34% |
| 2006-12-31 | CN¥605.80 Million ≈ $88.65 Million |
CN¥102.66 Million ≈ $15.02 Million |
0.169x | +245.73% |
| 2005-12-31 | CN¥577.16 Million ≈ $84.46 Million |
CN¥28.29 Million ≈ $4.14 Million |
0.049x | -63.17% |
| 2004-12-31 | CN¥609.02 Million ≈ $89.12 Million |
CN¥81.06 Million ≈ $11.86 Million |
0.133x | +249.67% |
| 2003-12-31 | CN¥573.94 Million ≈ $83.99 Million |
CN¥-51.04 Million ≈ $-7.47 Million |
-0.089x | -149.42% |
| 2002-12-31 | CN¥529.82 Million ≈ $77.53 Million |
CN¥95.34 Million ≈ $13.95 Million |
0.180x | +369.42% |
| 2001-12-31 | CN¥517.19 Million ≈ $75.68 Million |
CN¥-34.55 Million ≈ $-5.06 Million |
-0.067x | -123.55% |
| 2000-12-31 | CN¥344.80 Million ≈ $50.45 Million |
CN¥97.80 Million ≈ $14.31 Million |
0.284x | +410.31% |
| 1999-12-31 | CN¥334.58 Million ≈ $48.96 Million |
CN¥-30.58 Million ≈ $-4.48 Million |
-0.091x | +14.83% |
| 1998-12-31 | CN¥333.06 Million ≈ $48.74 Million |
CN¥-35.74 Million ≈ $-5.23 Million |
-0.107x | -- |
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined … Read more